Anticancer effect of spirooxindole derivatives

Chouhan, Neeraj Kumar; Talati, Mamta N.; Sharma, Mani; Pabbaraja, Srihari

doi:10.1016/b978-0-443-22324-2.00024-2

Spirooxindole 2024

DOI: 10.1016/b978-0-443-22324-2.00024-2

|View full text |Cite

Anticancer effect of spirooxindole derivatives

Neeraj Kumar Chouhan,

Mamta N. Talati,

Mani Sharma

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Book2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Peptide Vaccines in Cancer Immunotherapy

Chouhan,

Talati,

Sharma

et al. 2024

Advances in Medical Diagnosis, Treatment, and Care

View full text Add to dashboard Cite

Peptide vaccines offer promise in cancer immunotherapy, leveraging specificity, safety, and the potential for targeted immune responses against tumors. By incorporating multiple epitopes, they enhance immune recognition and can be customized based on individual patient profiles. This chapter explores peptide vaccines, emphasizing adjuvants that enhance efficacy while balancing safety. Traditional adjuvants like alum and oil-in-water emulsions promote immune cell activation, while toll-like receptor agonists stimulate innate immunity. Strategies to improve efficacy include combining peptide vaccines with other agents and overcoming challenges like low immunogenicity. Future research should refine adjuvant formulations and explore combination therapies to maximize the effectiveness of peptide vaccines against cancer.

show abstract

Peptide Vaccines in Cancer Immunotherapy

Chouhan,

Talati,

Sharma

et al. 2024

Advances in Medical Diagnosis, Treatment, and Care

View full text Add to dashboard Cite

show abstract

Immunoadjuvants in Cancer Immunotherapy

Talati,

Chouhan,

Sharma

et al. 2024

Advances in Medical Diagnosis, Treatment, and Care

View full text Add to dashboard Cite

Immunoadjuvants are crucial components of cancer immunotherapy that enhance immune responses against tumors. This chapter explores the underlying mechanisms and clinical uses of immunoadjuvants in cancer immunotherapy. Toll-like receptor agonists and STING agonists are two types of immunoadjuvants that activate immune cells and promote anti-tumor immunity. Cytokine-based immunoadjuvants have potential toxicity and off-target effects, but nanotechnology enables precision delivery to minimize these issues. Personalized approaches, biomarker discovery, and predictive modeling are important for optimizing treatment responses. Overall, immunoadjuvants are essential tools in cancer immunotherapy for generating strong and long-lasting anti-tumor immune responses. In conclusion, immunoadjuvants are critical components of cancer immunotherapy, playing a vital role in boosting strong and durable anti-tumor immune responses.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Anticancer effect of spirooxindole derivatives

Cited by 2 publications

References 36 publications

Peptide Vaccines in Cancer Immunotherapy

Peptide Vaccines in Cancer Immunotherapy

Immunoadjuvants in Cancer Immunotherapy

Contact Info

Product

Resources

About